Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proline-rich protein 5-like (PRR5L)
- Target
- PRR5L
- Molecular classification
- Other (mTOR complex protein; not a classical receptor, enzyme, transporter, or transcription factor), Regulatory complex subunit (TORC2 complex)
01
Overview
Proline-rich protein 5-like (PRR5L) is a regulatory subunit of the mTORC2 protein complex, controlling key aspects of cell growth, cytoskeletal organization, and survival. It modulates the substrate specificity of mTORC2, preferentially suppressing phosphorylation of PKC isoforms to control cell migration and influences stress response pathways by facilitating localization of ZFP36 to cytoplasmic stress granules and P-bodies, enhancing decay of select mRNAs. PRR5L is not a classical receptor, enzyme, or transporter, but acts as an accessory factor and fine-tuner in signal transduction networks including those relevant for cancer, cell migration, and metabolic regulation
- Other names
- PROTOR2Protor-2FLJ14213PROTOR-2Protein observed with Rictor-2PRR5LProline-rich protein 5-likeprotor-2
02
Mechanism of action
Drugs modulating mTOR signaling may indirectly affect PRR5L function as a component of mTORC2, influencing cell growth and metabolism
03
Biological functions
Regulation of mTORC2 activityRegulation of protein kinase C (PKC) phosphorylationRegulation of cell migrationStimulation of ZFP36-mediated mRNA decay (for stress response, including mRNAs such as TNF-alpha and GM-CSF)Required for localization of ZFP36 to stress granules and P-bodies
04
Disease associations
Cancer (implicated via mTOR signaling dysregulation)Potential roles in metabolic and stress response disorders (due to regulation of mTORC2 and ZFP36)"Other" (linked but not conclusively established with diseases affecting cell migration and survival due to involvement in mTOR network)
05
Safety considerations
No direct safety concerns for PRR5L as a therapeutic target reported due to lack of drugs directly targeting it. However, modulation of mTORC2 pathway can lead to metabolic and proliferative side effects
06
Interacting drugs
None specifically identified that directly target PRR5L. mTOR inhibitors (such as rapamycin and its analogs) affect the mTORC2 complex where PRR5L functions, but PRR5L itself is not the direct drug target
07
Biomarkers
None established specifically for PRR5L for patient selection or efficacy monitoring. General mTORC2 activity may use downstream signals (e.g., PKC, AKT phosphorylation) as biomarkers
Beyond the preview
Go deeper on Proline-rich protein 5-like (PRR5L).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proline-rich protein 5-like (PRR5L).